Patents by Inventor F. Gary Toback
F. Gary Toback has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140287995Abstract: The present disclosure provides pharmaceutical formulations including a kidney growth factor peptide and one or more excipients, wherein the formulations have a pH of greater than about 6.8. The disclosure also provides processes for preparing the formulation and products prepared by such processes.Type: ApplicationFiled: October 29, 2012Publication date: September 25, 2014Inventors: F. Gary Toback, Ann Berger
-
Patent number: 8791068Abstract: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease and gastric ulcers.Type: GrantFiled: August 30, 2012Date of Patent: July 29, 2014Assignee: The University of ChicagoInventors: Terence E. Martin, F. Gary Toback, Margaret Walsh-Reitz
-
Patent number: 8741838Abstract: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease, mucositis, and gastric ulcers.Type: GrantFiled: March 8, 2011Date of Patent: June 3, 2014Assignee: The University of ChicagoInventors: F. Gary Toback, Terence E. Martin, Margaret M. Walsh-Reitz
-
Publication number: 20130086701Abstract: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease and gastric ulcers.Type: ApplicationFiled: August 30, 2012Publication date: April 4, 2013Applicant: THE UNIVERSITY OF CHICAGOInventors: Terence Martin, F. Gary Toback, Margaret Walsh-Reitz
-
Patent number: 8278269Abstract: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease and gastric ulcers.Type: GrantFiled: March 29, 2002Date of Patent: October 2, 2012Assignee: The University of ChicagoInventors: Terence Martin, F. Gary Toback, Margaret Walsh-Reitz
-
Publication number: 20110245168Abstract: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease, mucositis, and gastric ulcers.Type: ApplicationFiled: March 8, 2011Publication date: October 6, 2011Applicant: THE UNIVERSITY OF CHICAGOInventors: F. Gary Toback, Terence E. Martin, Margaret M. Walsh-Reitz
-
Patent number: 8017576Abstract: Methods and compositions of AMP-18 derived peptides enablingly demonstrate that AMP-18 derived peptide compositions surprisingly reduce mucositis in mammals. Methods and peptide compositions treat mucositis, delays the onset or duration of mucositis, including cancer therapy-induced mucositis are disclosed. AMP 77-97 peptide derived from human AMP-18 protein alleviates cancer therapy-induced mucositis.Type: GrantFiled: May 9, 2006Date of Patent: September 13, 2011Assignee: The University of ChicagoInventor: F. Gary Toback
-
Patent number: 7910543Abstract: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease, mucositis, and gastric ulcers.Type: GrantFiled: October 23, 2009Date of Patent: March 22, 2011Assignee: The University of ChicagoInventors: F. Gary Toback, Terence E. Martin, Margaret M. Walsh-Reitz
-
Publication number: 20100113356Abstract: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease, mucositis, and gastric ulcers.Type: ApplicationFiled: October 23, 2009Publication date: May 6, 2010Applicant: THE UNIVERSITY OF CHICAGOInventors: F. Gary Toback, Terence E. Martin, Margaret M. Walsh-Reitz
-
Patent number: 7629317Abstract: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins, making the proteins candidates for therapies in inflammatory bowel disease, mucositis, and gastric ulcers.Type: GrantFiled: May 11, 2004Date of Patent: December 8, 2009Assignee: The University of ChicagoInventors: F. Gary Toback, Terence E. Martin, Margaret M. Walsh-Reitz
-
Patent number: 7557083Abstract: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Control of mammalian gastro-intestinal tissues growth and repair is facilitated by the use of the proteins, making the proteins candidates for therapies.Type: GrantFiled: March 29, 2002Date of Patent: July 7, 2009Assignee: The University of ChicagoInventors: Terence E. Martin, F. Gary Toback, Thomas C. Powell, Miriana Choudhary, legal representative, Kan Agarwal
-
Patent number: 7550438Abstract: Novel growth peptides derived from protein factors having molecular weights of about 22 and 45 kDa stimulate mitogenic activity of epithelial, but not fibroblastic cells, in particular, kidney epithelial cells. A source of the factors is scrape-wounded kidney epithelial cells in culture. Synthetic peptides having sixteen amino acids or less, in particular a hexapeptide, YPQGNH (SEQ ID NO: 2) maintain the mitogenic activity. The peptide AQPYPQGNHEASYG (14-Ser) (SEQ ID NO: 15) is effective in reversing acute renal failure in animals. The growth-promoting characteristics of the 22 and 45 kDa proteins and the peptides are useful in treating and diagnosing patients with kidney disease. Nucleotide sequences that encode the factor are useful to develop probes to locate similar factors, to identify genetic disorders involving the factor, and to produce the factor by genetic recombinant methods. The nucleotide sequences and fragments thereof, are also useful for diagnosis and treatment of kidney disorders.Type: GrantFiled: November 6, 2006Date of Patent: June 23, 2009Assignee: The University of ChicagoInventors: F. Gary Toback, Margaret M. Walsh-Reitz
-
Publication number: 20080194479Abstract: Methods and compositions of AMP-18 derived peptides enablingly demonstrate that AMP-18 derived peptide compositions surprisingly reduce mucositis in mammals. Methods and peptide compositions treat mucositis, delays the onset or duration of mucositis, including cancer therapy-induced mucositis are disclosed. AMP 77-97 peptide derived from human AMP-18 protein alleviates cancer therapy-induced mucositis.Type: ApplicationFiled: May 9, 2006Publication date: August 14, 2008Applicant: THE UNIVERSITY OF CHICAGOInventor: F. Gary Toback
-
Patent number: 7160864Abstract: Novel growth peptides derived from protein factors having molecular weights of about 22 and 45 kDa stimulate mitogenic activity of epithelial, but not fibroblastic cells, in particular, kidney epithelial cells. A source of the factors is scrape-wounded kidney epithelial cells in culture. Synthetic peptides having sixteen amino acids or less, in particular a hexapeptide, YPQGNH (SEQ ID NO: 2) maintain the mitogenic activity. The peptide AQPYPQGNHEASYG (14-Ser) (SEQ ID NO: 15) is effective in reversing acute renal failure in animals. The growth-promoting characteristics of the 22 and 45 kDa proteins and the peptides are useful in treating and diagnosing patients with kidney disease. Nucleotide sequences that encode the factor are useful to develop probes to locate similar factors, to identify genetic disorders involving the factor, and to produce the factor by genetic recombinant methods. The nucleotide sequences and fragments thereof, are also useful for diagnosis and treatment of kidney disorders.Type: GrantFiled: July 16, 2004Date of Patent: January 9, 2007Assignee: The University of ChicagoInventors: F. Gary Toback, Margaret M. Walsh-Reitz
-
Patent number: 6734289Abstract: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Control of mammalian gastro-intestinal tissues growth and repair is facilitated by the use of the proteins, making the proteins candidates for therapies.Type: GrantFiled: March 29, 2001Date of Patent: May 11, 2004Assignee: The University of ChicagoInventors: Terence Martin, F. Gary Toback, C. Thomas Powell, Kan Agarwal
-
Publication number: 20030176340Abstract: Novel growth peptides derived from protein factors having molecular weights of about 22 and 45 kDa stimulate mitogenic activity of epithelial, but not fibroblastic cells, in particular, kidney epithelial cells. A source of the factors is scrape-wounded kidney epithelial cells in culture. Synthetic peptides having sixteen amino acids or less, in particular a hexapeptide, YPQGNH (SEQ ID NO: 2) maintain the mitogenic activity. The peptide AQPYPQGNHEASYG (14-Ser) (SEQ ID NO: 15) is effective in reversing acute renal failure in animals. The growth-promoting characteristics of the 22 and 45 kDa proteins and the peptides are useful in treating and diagnosing patients with kidney disease. Nucleotide sequences that encode the factor are useful to develop probes to locate similar factors, to identify genetic disorders involving the factor, and to produce the factor by genetic recombinant methods. The nucleotide sequences and fragments thereof, are also useful for diagnosis and treatment of kidney disorders.Type: ApplicationFiled: November 22, 2002Publication date: September 18, 2003Inventors: F. Gary Toback, Margaret M. Walsh-Reitz
-
Publication number: 20030158115Abstract: An autocrine crystal adhesion inhibitor called CAI is an anionic, sialic acid-containing glycoprotein secreted by kidney epithelial cells that blocks adhesion of calcium oxalate monohydrate (COM) crystals to the cell surfaces. Novel amino acid sequences are shown for the amino-acid terminus and 6 interval fragments. Persons may be classified according to risk of developing kidney stones, by measuring the amount of CAI in a biological sample. Treatment efficacy is also monitored by this method. CAI is administered in vivo to prevent nephrolithiasis. A rapid, simple assay to detect agents that inhibit adhesion of COM crystals to the surface of kidney epithelial cells is characterized.Type: ApplicationFiled: November 18, 2002Publication date: August 21, 2003Inventors: F. Gary Toback, John C. Lieske
-
Patent number: 6534290Abstract: Novel growth peptides derived from protein factors having molecular weights of about 22 and 45 kDa stimulate mitogenic activity of epithelial, but not fibroblastic cells, in particular, kidney epithelial cells. A source of the factors is scrape-wounded kidney epithelial cells in culture. Synthetic peptides having sixteen amino acids or less, in particular a hexapeptide, YPQGNH (SEQ ID NO: 2) maintain the mitogenic activity. The peptide AQPYPQGNHEASYG (14-Ser) (SEQ ID NO: 15) is effective in reversing acute renal failure in animals. The growth-promoting characteristics of the 22 and 45 kDa proteins and the peptides are useful in treating and diagnosing patients with kidney disease. Nucleotide sequences that encode the factor are useful to develop probes to locate similar factors, to identify genetic disorders involving the factor, and to produce the factor by genetic recombinant methods. The nucleotide sequences and fragments thereof, are also useful for diagnosis and treatment of kidney disorders.Type: GrantFiled: June 9, 2000Date of Patent: March 18, 2003Assignee: Arch Development Corp.Inventors: F. Gary Toback, Margaret M. Walsh-Reitz
-
Publication number: 20030017548Abstract: A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA, cDNA and the AMP-18 protein are sequenced for human, mouse and pig. The AMP-18 protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Control of mammalian gastro-intestinal tissues growth and repair is facilitated by the use of the proteins, making the proteins candidates for therapies.Type: ApplicationFiled: March 29, 2001Publication date: January 23, 2003Inventors: Terence Martin, F. Gary Toback, C. Thomas Powell, Kan Agarwal
-
Patent number: 6482934Abstract: An autocrine crystal adhesion inhibitor called CAI is an anionic, sialic acid-containing glycoprotein secreted by kidney epithelial cells that blocks adhesion of calcium oxalate monohydrate (COM) crystals to the cell surfaces. Novel amino acid sequences are shown for the amino-acid terminus and 6 interval fragments. Persons may be classified according to risk of developing kidney stones, by measuring the amount of CAI in a biological sample. Treatment efficacy is also monitored by this method. CAI is administered in vivo to prevent nephrolithiasis. A rapid, simple assay to detect agents that inhibit adhesion of COM crystals to the surface of kidney epithelial cells is characterized.Type: GrantFiled: March 28, 2000Date of Patent: November 19, 2002Assignee: ARCH Development Corp.Inventors: F. Gary Toback, John C. Lieske